Tunnell Consulting’s Kip Wolf Delivers Insights into the Future of Pharmaceuticals Industry

08:30 EDT 22 Jun 2017 | PR Web

Industry visionary Kip Wolf provides clarity, insights and innovative solutions to the changes and challenges of the pharma industry

King of Prussia, PA (PRWEB) June 22, 2017

Tunnell Consulting’s thought leaders, bringing industry knowledge and superior results to clients throughout the biopharma and life sciences industries, continue to be in demand for their insights and commentary on the rapid changes the industry is seeing. Tunnell’s Kip Wolf will be speaking on “The State of Information Governance in the Biopharmaceutical Industry” at the Information Governance Pharmaceutical Roundtable on July 13th, in Northbrook, Illinois. Highlighting the rapid changes and challenges of information governance, Wolf will visit topics such as challenges in information governance, including structured data; trends in the industry; and best practices for success.

“At this event, we will be talking about applying creative design to information governance and risk-based approaches to some of the most pressing information management and data integrity challenges,” said Wolf. “Data integrity issues are a common citation in recent FDA Warning Letters, and we’ll be talking about innovative thinking and non-traditional approaches to information governance which can improve data integrity and deliver a true competitive advantage.”

Wolf’s more than 25 years of experience in quality assurance and regulatory compliance has proven a valuable asset to Tunnell clients. An expert in business transformation, new business development, organizational change leadership and program and project management, he has held several high-level management positions at some of the world’s most prominent life sciences companies, including Johnson and Johnson, Merck & Co., and Wyeth Pharmaceuticals. He is a certified Project Management Professional (PMP) and a Program Management Professional (PgMP).

Wolf and other Tunnell thought leaders are at the forefront of the industry, guiding the most important decisions pharma and life sciences companies must make. Wolf and the rest of the team are thought leaders who not only understand the industry as it is now, but know where it is going in the years to come. Most recently, Tunnell’s commentary was seen in Innovation Excellence, in discussing how to develop a quality culture in a pharma company to create a “right first time” approach to delivery.

Tunnell Consulting’s regulatory services begin at the evaluation stage, running from drug discovery to market approval. In addition to supporting all regulatory submissions and serving as liaison to regulatory authorities, Tunnell provides expert leadership to internal project teams and works with management to create specific and effective regulatory strategies.

About Tunnell Consulting
Founded in 1962 and serving many of the world’s leading life sciences firms and government agencies, Tunnell Consulting, Inc. integrates strategic, technical, process, and organizational skills to design and implement sustainable solutions that exactly meet client needs. With deep industry knowledge, extensive scientific credentials, and superior measurable results, we consistently boost the operating performance of each unique client we serve. To learn more, visit us online at

For the original version on PRWeb visit:


More From BioPortfolio on "Tunnell Consulting’s Kip Wolf Delivers Insights into the Future of Pharmaceuticals Industry"

Quick Search


Relevant Topics

Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...